Department of Oncology, University Hospital of Geneva, 1205 Geneva, Switzerland.
Center for Translational Research in Onco-Haematology, University of Geneva, 1205 Geneva, Switzerland.
Int J Mol Sci. 2021 Mar 28;22(7):3493. doi: 10.3390/ijms22073493.
Glioblastoma is the most frequent primary neoplasm of the central nervous system and still suffers from very poor therapeutic impact. No clear improvements over current standard of care have been made in the last decade. For other cancers, but also for brain metastasis, which harbors a very distinct biology from glioblastoma, immunotherapy has already proven its efficacy. Efforts have been pursued to allow glioblastoma patients to benefit from these new approaches, but the road is still long for broad application. Here, we aim to review key glioblastoma immune related characteristics, current immunotherapeutic strategies being explored, their potential caveats, and future directions.
胶质母细胞瘤是中枢神经系统最常见的原发性肿瘤，其治疗效果仍然很差。在过去的十年中，没有明显的改善超过目前的护理标准。对于其他癌症，甚至对于脑转移瘤，它具有与胶质母细胞瘤截然不同的生物学特性，免疫疗法已经证明了其疗效。人们一直在努力使胶质母细胞瘤患者能够从这些新方法中受益，但要广泛应用还有很长的路要走。在这里，我们旨在回顾胶质母细胞瘤的关键免疫相关特征、目前正在探索的免疫治疗策略、它们的潜在局限性以及未来的方向。
